Inactive Instrument

MediGene AG Xetra

DE0005020903

Biotechnology & Medical Research

End-of-day quote Xetra Other stock markets
- ^EUR	-

07-03	Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China	CI
06-27	Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness	CI

MediGene AG : MediGene Initiates Clinical Formulation Study of RhuDex® for the Oral Treatment of Autoimmune Diseases

January 25, 2012 at 02:02 am

MarketScreener.com By

Press Release MediGene Initiates Clinical Formulation Study of RhuDex® for the Oral Treatment of Autoimmune Diseases

Latest news about MediGene AG

Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China	07-03	CI
Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness	06-27	CI
Medigene, BioNTech Extend Cancer Immunotherapy Partnership	05-21	MT
Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term	05-21	CI
Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	05-15	CI
Medigene Ag Maintains Earnings Guidance for 2024	05-14	CI
Medigene Boosts Share Capital Via Rights Offering, Private Placement	05-08	MT
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 - Targeted T Cell Receptor	05-02	CI
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein	05-02	CI
Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process	04-25	CI
Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	04-08	CI
Medigene Gets European Patent for T-Cell Receptor Technology	04-04	MT
Medigene AG Secures European Patent for Its iM-TCR Technology	04-04	CI
Medigene AG Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Transcript : Medigene AG, 2023 Earnings Call, Mar 28, 2024	03-28
Medigene Ag Provides Earnings Guidance for 2024	03-28	CI
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy	03-04	CI
Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors	02-12	CI
Medigene AG Maintains Financial Guidance for the Fiscal Year 2023	11-21	CI
Medigene Presents New Data for MDG 2011, the First TCR in a Novel Kras Library	11-04	CI
Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing	23-10-23	CI
Medigene to Present New Pre-Clinical Data for Pipeline TCR-T Therapies At the ESMO Congress 2023	23-10-16	CI
Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types	23-08-23	CI
Medigene AG Provides Revenue Guidance for 2023	23-08-17	CI
Transcript : Medigene AG, H1 2023 Earnings Call, Aug 17, 2023	23-08-17

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	126B
REGENERON PHARMACEUTICALS, INC.	+24.67%	118B
ARGENX SE	+24.13%	27.87B
BIONTECH SE	-17.74%	20.95B
GENMAB A/S	-14.83%	16.92B
BEIGENE, LTD.	-15.21%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.08B

Bio Therapeutic Drugs

MediGene AG Xetra

Equities

DE0005020903

Biotechnology & Medical Research

MediGene AG : MediGene Initiates Clinical Formulation Study of RhuDex® for the Oral Treatment of Autoimmune Diseases

Latest news about MediGene AG

Chart MediGene AG

Company Profile

Sector Bio Therapeutic Drugs